CDK12 and breast cancer: Delivery of ICD inducers, such as SR-4835 (a CDK12/13-specific inhibitor), RIG-I agonists and chemotherapeutics, as well as photothermal agents, with synthetic nanoparticles, has been confirmed to have therapeutic potential in several preclinical models of breast cancer [45–47].